{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:09:58Z","timestamp":1790233798327,"version":"4.1.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001771","name":"University of Newcastle Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001771","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013027","name":"Calvary Mater Newcastle","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013027","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Maitland Cancer Appeal"},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"crossref","award":["14CDF117"],"award-info":[{"award-number":["14CDF117"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001081","name":"Hunter Medical Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001081","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,17]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Drug repurposing offers the opportunity for chemotherapy to be used to reestablish sensitivity to immune checkpoint blockade (ICB) therapy. Here we investigated the clinical and translational aspects of an early phase II study of azacitidine and carboplatin priming for anti-PDL1 immunotherapy (avelumab) in patients with advanced ICB-resistant melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>A total of 20 participants with ICB-resistant metastatic melanoma received 2 \u00d7 4-week cycles of azacitidine and carboplatin followed by ICB rechallenge with anti-PD-L1 avelumab. The primary objective was overall response rate after priming and ICB rechallenge. Secondary objectives were clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS). Translational correlation analysis of HLA-A and PD-L1 expression, RNA sequencing, and reduced representation bisulfite sequencing of biopsies at baseline, after priming and after six cycles of avelmuab was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The overall response rate (ORR) determined after azacitidine and carboplatin priming was 10% (2\/20) with two partial responses (PR). The ORR determined after priming followed by six cycles of avelumab (week 22) was 10%, with 2 of 20 participants achieving immune partial response (iPR). The CBR for azacitidine and carboplatin priming was 65% (13\/20) and after priming followed by six cycles of avelumab CBR was 35% (n = 7\/20). The median PFS was 18.0 weeks [95% confidence interval (CI): 14.87\u201321.13 weeks] and the median OS was 47.86 weeks (95% CI: 9.67\u201386.06 weeks). Translational correlation analysis confirmed HLA-A generally increased after priming with azacitidine and carboplatin, particularly if it was absent at the start of treatment. Average methylation of CpGs across the HLA-A locus was decreased after priming and T cells, in particular CD8+, showed the greatest increase in infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Priming with azacitidine and carboplatin can induce disease stabilization and resensitization to ICB for metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>There are limited treatments for melanoma once resistance to ICB occurs. Chemotherapy induces immune-related responses and may be repurposed to reinstate the response to ICB. This study provides the first evidence that chemotherapy can provide clinical benefit and increase OS for ICB-resistant melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0128","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:15:35Z","timestamp":1659086135000},"page":"814-826","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade\u2013resistant Melanoma for Anti-PD-L1 Rechallenge"],"prefix":"10.1158","volume":"2","author":[{"given":"Andre","family":"van der Westhuizen","sequence":"first","affiliation":[{"name":"1Hunter Medical Research Institute and School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia."},{"name":"2Department of Medical Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Lyle","sequence":"additional","affiliation":[{"name":"3Liz Plummer Cancer Centre, Cairns Hospital, Cairns, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3380-5417","authenticated-orcid":true,"given":"Moira C.","family":"Graves","sequence":"additional","affiliation":[{"name":"1Hunter Medical Research Institute and School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"4School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-7728","authenticated-orcid":true,"given":"Jason W. H.","family":"Wong","sequence":"additional","affiliation":[{"name":"4School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Cornall","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Ren","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna","family":"Pugliese","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Levy","sequence":"additional","affiliation":[{"name":"5Department of Surgery, Calvary Mater Hospital, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-1708","authenticated-orcid":true,"given":"Adeeb","family":"Majid","sequence":"additional","affiliation":[{"name":"5Department of Surgery, Calvary Mater Hospital, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo E.","family":"Vilain","sequence":"additional","affiliation":[{"name":"1Hunter Medical Research Institute and School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia."},{"name":"6Department of Anatomical Pathology, Pathology North, NSW Health Pathology, Newcastle, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6047-1694","authenticated-orcid":true,"given":"Nikola A.","family":"Bowden","sequence":"additional","affiliation":[{"name":"1Hunter Medical Research Institute and School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.3390\/cancers12113374","article-title":"Tumor MHC expression guides first-line immunotherapy selection in melanoma","volume":"12","author":"Shklovskaya","year":"2020","journal-title":"Cancers"},{"key":"2023031315411960300_","first-page":"R31","article-title":"Linking the epigenetic. 'language' of covalent histone modifications to cancer","author":"Hake","year":"2007","journal-title":"Br J Cancer"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CMR.0b013e328338a35a","article-title":"Aberrant DNA methylation in malignant melanoma","volume":"20","author":"Schinke","year":"2010","journal-title":"Melanoma Res"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2014.08.010","article-title":"Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors","volume":"354","author":"Nie","year":"2014","journal-title":"Cancer Lett"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1158\/0008-5472.CAN-05-0695","article-title":"Characterization of DNA demethylation effects induced by 5-Aza-2\u02b9-deoxycytidine in patients with myelodysplastic syndrome","volume":"65","author":"Mund","year":"2005","journal-title":"Cancer Res"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13148-015-0065-5","article-title":"Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy","volume":"7","author":"Tsimberidou","year":"2015","journal-title":"Clin Epigenetics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13148-015-0131-z","article-title":"Epigenetic synergy between decitabine and platinum derivatives","volume":"7","author":"Qin","year":"2015","journal-title":"Clin Epigenetics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12885-018-4010-9","article-title":"Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma","volume":"18","author":"Budden","year":"2018","journal-title":"BMC Cancer"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"e112880","DOI":"10.1371\/journal.pone.0112880","article-title":"Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma","volume":"9","author":"Viet","year":"2014","journal-title":"PLoS One"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bcp.2012.01.009","article-title":"DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs","volume":"83","author":"Charlet","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7754\/Clin.Lab.2015.150429","article-title":"5-Aza-2\u02b9-Deoxycytidine and CDDP synergistically induce apoptosis in renal carcinoma cells via enhancing the APAF-1 activity","volume":"61","author":"Zhu","year":"2015","journal-title":"Clin Lab"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4161\/epi.28601","article-title":"Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer","volume":"9","author":"Zhang","year":"2014","journal-title":"Epigenetics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2018.08.030","article-title":"Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer","volume":"151","author":"Scurry","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1038\/s41467-019-13035-2","article-title":"Transposable element expression in tumors is associated with immune infiltration and increased antigenicity","volume":"10","author":"Kong","year":"2019","journal-title":"Nat Commun"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"2023031315411960300_","article-title":"RepeatMasker Open-4.0","author":"Smit","year":"2013\u20132015"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/bioinformatics\/btr167","article-title":"Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications","volume":"27","author":"Krueger","year":"2011","journal-title":"Bioinformatics"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmed.2019.00113","article-title":"Monitoring patient response to pembrolizumab with peripheral blood exhaustion marker profiles","volume":"6","author":"Graves","year":"2019","journal-title":"Front Med"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"e00808","DOI":"10.1002\/prp2.808","article-title":"Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers","volume":"9","author":"Navani","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","article-title":"Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/0008-5472.CAN-17-1492","article-title":"Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs","volume":"78","author":"Fang","year":"2018","journal-title":"Cancer Res"},{"key":"2023031315411960300_","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1078-0432.CCR-17-3055","article-title":"A phase I clinical trial of guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer: clinical, pharmacokinetic, and pharmacodynamic analyses","volume":"24","author":"Matei","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0128\/3184205\/crc-22-0128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/814\/3282560\/crc-22-0128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/814\/3282560\/crc-22-0128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T22:45:01Z","timestamp":1700865901000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/8\/814\/707822\/Repurposing-Azacitidine-and-Carboplatin-to-Prime"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,17]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0128","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545465","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550950","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545471.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545465.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550950.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545471","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2022.02.03.22270286","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}